Description: <b>Soursop or Brazilian paw paw or guanabana.</b> People use fruit, roots, seeds and leaves.
Graviola, also known as Annona muricata, is a tropical fruit-bearing tree native to the Americas.<br>
Graviola (Annona muricata; soursop) contains annonaceous acetogenins (e.g., annonacin, bullatacin-class compounds) that are widely described as mitochondrial complex I inhibitors, producing ATP depletion and downstream stress signaling that can lead to cell-cycle arrest and apoptosis in many in-vitro cancer models. A key real-world constraint is safety: epidemiology in the French Caribbean reports an association between high Annonaceae consumption and atypical parkinsonism, and animal data indicate annonacin can enter brain tissue and drive ATP depletion with neurodegenerative patterns under chronic exposure; therefore Graviola products should be treated as higher-risk than many polyphenols and should not be framed as a casual long-term supplement.<br>
<br>
GLUT1 inhibitor?<br>
The major pathways involved in Graviola's anti-cancer effects include:<br>
-Reported reduction of glucose uptake (e.g., GLUT1 expression) in selected tumor models.: Graviola extracts have been shown to inhibit the activity of lactate dehydrogenase (LDH), a key enzyme involved in glycolysis, the process by which cancer cells produce energy. By inhibiting LDH, Graviola reduces the production of lactate, a key metabolite that fuels cancer cell growth.(likely secondary to mitochondrial ATP depletion)<br>
-Inhibition of glucose uptake: Graviola extracts have also been shown to inhibit the uptake of glucose by cancer cells, further reducing their energy production.<br>
-Inhibition of the PI3K/AKT pathway: The PI3K/AKT pathway is a key signaling pathway involved in cell survival and proliferation. Graviola extracts have been shown to inhibit this pathway, leading to reduced cancer cell growth and survival.<br>
-Induction of apoptosis: Graviola extracts have been shown to induce apoptosis in cancer cells by activating pro-apoptotic proteins and inhibiting anti-apoptotic proteins.<br>
<br>
The major compounds responsible for Graviola's anti-cancer effects are:<br>
Annonaceous acetogenins: These are a group of compounds found in Graviola that have been shown to inhibit cancer cell growth and induce apoptosis.<br>
<br>
<p><b>Graviola (Annona muricata)</b> — also known as soursop, guanábana, guyabano, and Brazilian pawpaw, is a tropical Annonaceae tree whose fruit, leaves, bark, roots, and seeds contain multiple phytochemical classes, particularly annonaceous acetogenins such as annonacin, along with flavonoids, alkaloids, and phenolics. It is best classified as a botanical extract / medicinal plant rather than a single drug; the standard abbreviation A. muricata or AM is commonly used. Anticancer activity is predominantly attributed to acetogenin-mediated mitochondrial complex I inhibition, although crude leaf extracts have broader and composition-dependent actions. Different plant parts and commercial preparations are not pharmacologically interchangeable, and annonacin content varies substantially between products.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Mitochondrial respiratory-chain complex I inhibition by annonaceous acetogenins, causing impaired oxidative phosphorylation, ATP depletion, and energetic stress.</li>
<li>Mitochondrial apoptosis through Bax/Bcl-2 rebalancing, mitochondrial membrane dysfunction, cytochrome-c release, and caspase activation.</li>
<li>Suppression of tumor energy metabolism, including reduced glucose uptake / GLUT expression and glycolytic outputs in selected models.</li>
<li>Cell-cycle arrest and suppression of proliferative signaling, including cyclin/CDK and context-dependent PI3K/AKT, EGFR, Hedgehog, and related survival pathways.</li>
<li>Suppression of invasion, migration, angiogenic signaling, and inflammatory/survival transcription programs including NF-κB in selected tumor models.</li>
<li>ER-stress and autophagy-associated stress responses in some cancer models.</li>
<li>ROS/redox modulation secondary to mitochondrial dysfunction; ROS can increase in tumor cells, but the direction is extract- and model-dependent and should not be treated as a universal primary mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human pharmacokinetic characterization of Graviola extracts and individual acetogenins remains inadequate. Annonacin is lipophilic, and animal studies demonstrate systemic distribution and penetration into brain tissue, which is clinically relevant to its neurotoxicity signal. Commercial leaf preparations show substantial variation in annonacin concentration and acetogenin composition, preventing reliable conversion of a labeled mass of leaf extract into a defined systemic acetogenin exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer evidence derives from concentrated extracts or isolated acetogenins tested directly against cultured tumor cells. Comparable free concentrations in human tumors following oral Graviola supplementation have not been established. Therefore, concentrations producing cytotoxicity in vitro cannot presently be assumed to be systemically achievable or safe. This exposure uncertainty is especially important because mitochondrial complex I inhibition is not tumor-specific and is also a mechanistic basis for annonacin neurotoxicity.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical, with limited small-human evidence. A small randomized double-blind placebo-controlled study in 30 colorectal-cancer patients used 300 mg/day of an ethanol-soluble A. muricata leaf fraction for 8 weeks and reported biological/ex-vivo cytotoxicity outcomes rather than established tumor-response or survival efficacy. Additional observational human studies exist, including combination products, but they do not establish Graviola as an effective cancer therapy. No regulatory authority has approved Graviola or annonacin as an anticancer treatment. A major translation constraint is chronic neurotoxicity: epidemiologic and experimental evidence links substantial Annonaceae exposure and annonacin-mediated complex I inhibition with atypical parkinsonism/neurodegenerative injury.</p>
<h3>Graviola Cancer-Relevant Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial complex I and oxidative phosphorylation</td>
<td>Complex I ↓; oxidative phosphorylation ↓; ATP ↓; energetic stress ↑</td>
<td>Complex I ↓ with sufficient exposure; neuronal ATP depletion and toxicity risk ↑</td>
<td>P, R</td>
<td>Bioenergetic collapse</td>
<td>Core acetogenin mechanism. Annonacin and related annonaceous acetogenins inhibit mitochondrial NADH dehydrogenase / complex I. This is a central upstream mechanism but is not intrinsically tumor-selective.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial ROS and oxidative stress</td>
<td>ROS ↑; oxidative stress ↑; mitochondrial dysfunction ↑ (dose-dependent) (model-dependent)</td>
<td>ROS ↓ with antioxidant-rich extracts; ROS ↑ with sufficient acetogenin exposure (context-dependent)</td>
<td>P, R</td>
<td>Oxidative stress amplification and apoptosis</td>
<td>Complex I inhibition can increase mitochondrial ROS while decreasing ATP. In cancer models, ROS can function as an active mediator of apoptosis; antioxidant rescue has suppressed Graviola-induced ROS and cell death. Whole extracts can also exhibit antioxidant activity, making the direction preparation- and exposure-dependent.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial apoptosis</td>
<td>Bax ↑; Bcl-2 ↓; mitochondrial membrane potential ↓; cytochrome-c release ↑; caspase-9/3/7 ↑; apoptosis ↑</td>
<td>↔ at low exposure; apoptosis or mitochondrial toxicity ↑ at sufficient acetogenin exposure</td>
<td>R, G</td>
<td>Programmed cell death</td>
<td>A major downstream consequence of mitochondrial energetic and oxidative stress. Bax/Bcl-2 modulation, mitochondrial membrane disruption, and caspase activation are repeatedly reported in Graviola and isolated-acetogenin cancer models.</td>
</tr>
<tr>
<td>4</td>
<td>Glucose uptake and glycolytic metabolism</td>
<td>GLUT1 ↓; GLUT4 ↓; glucose uptake ↓; HK2 ↓; LDH/LDHA ↓ (model-dependent)</td>
<td>↔ or glucose regulation (context-dependent)</td>
<td>R, G</td>
<td>Metabolic restriction</td>
<td>Graviola can suppress glucose uptake and glycolytic metabolism in selected tumor models. GLUT1 is better described as downregulated rather than as a proven direct pharmacologic target.</td>
</tr>
<tr>
<td>5</td>
<td>Cell-cycle and proliferative control</td>
<td>Cyclin D1 ↓; cyclin/CDK signaling ↓; cell-cycle arrest ↑; proliferation ↓</td>
<td>↔ (dose-dependent)</td>
<td>G</td>
<td>Cytostasis</td>
<td>Both annonacin and whole extracts can induce cell-cycle arrest. The specific checkpoint varies among cancer types and extract preparations.</td>
</tr>
<tr>
<td>6</td>
<td>PI3K AKT survival signaling</td>
<td>PI3K ↓; AKT phosphorylation ↓; survival signaling ↓ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Survival-signal suppression</td>
<td>Suppression of PI3K/AKT signaling has been demonstrated in selected Graviola cancer models and can reinforce apoptosis and growth inhibition.</td>
</tr>
<tr>
<td>7</td>
<td>NF-κB inflammatory and survival signaling</td>
<td>NF-κB ↓; inflammatory signaling ↓; anti-apoptotic signaling ↓</td>
<td>Inflammatory signaling ↓ (context-dependent)</td>
<td>R, G</td>
<td>Inflammatory and survival pathway suppression</td>
<td>NF-κB inhibition contributes to reduced survival and inflammatory signaling in several extract-based models but is less consistently established than mitochondrial mechanisms.</td>
</tr>
<tr>
<td>8</td>
<td>EGFR and growth-factor signaling</td>
<td>EGFR ↓; downstream proliferation signaling ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Growth suppression</td>
<td>EGFR downregulation or inhibition of EGFR-associated signaling has been reported in selected breast and other cancer models but should not be generalized across all tumor types.</td>
</tr>
<tr>
<td>9</td>
<td>Hedgehog GLI signaling</td>
<td>Shh ↓; SMO ↓; GLI1 ↓; GLI2 ↓; proliferation ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Developmental growth-pathway suppression</td>
<td>Reported particularly in skin-cancer and selected tumor models. This is a contextual rather than universal Graviola mechanism.</td>
</tr>
<tr>
<td>10</td>
<td>ER stress and unfolded-protein response</td>
<td>PERK/eIF2α signaling ↑; GRP78/BiP ↑; CHOP ↑; ER stress ↑</td>
<td>↔ or cellular stress ↑ at higher exposure</td>
<td>R, G</td>
<td>Stress-induced apoptosis</td>
<td>ER-stress activation has been demonstrated in selected cancer models and may cooperate with mitochondrial energetic stress and ROS-mediated apoptosis.</td>
</tr>
<tr>
<td>11</td>
<td>HIF-1α and hypoxic tumor signaling</td>
<td>HIF-1α ↓; hypoxia-associated survival signaling ↓ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Hypoxic adaptation suppression</td>
<td>HIF-1α suppression has been reported in selected models and may be secondary to altered cellular metabolism, mitochondrial function, and redox signaling.</td>
</tr>
<tr>
<td>12</td>
<td>Migration invasion and EMT-associated signaling</td>
<td>Migration ↓; invasion ↓; MMP9 ↓; FAK signaling ↓; EMT-associated phenotype ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Graviola extracts can reduce migration and invasion in several preclinical tumor systems, but specific signaling effects vary substantially with tumor model and extract composition.</td>
</tr>
<tr>
<td>13</td>
<td>Angiogenic signaling</td>
<td>VEGF ↓; angiogenic signaling ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-angiogenic activity</td>
<td>Reduced VEGF and angiogenic signaling have been reported preclinically and are likely downstream of broader metabolic, inflammatory, and hypoxic signaling changes.</td>
</tr>
<tr>
<td>14</td>
<td>Clinical Translation Constraint</td>
<td>Human tumor exposure uncertain; therapeutic concentration not established</td>
<td>Neurotoxicity risk ↑ with chronic or sufficient annonaceous acetogenin exposure</td>
<td>G</td>
<td>Limits therapeutic translation</td>
<td>No validated anticancer dose, therapeutic window, or standardized acetogenin exposure exists. Commercial products vary substantially in annonacin content. Human oncology evidence is limited, while mitochondrial complex I inhibition and chronic annonacin exposure create a significant neurotoxicity concern.</td>
</tr>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>